|
Totally high-risk patient populations
|
5
|
4.67 (2.18, 9.99); I2 = 77.7%
|
|
Low risk of bias
|
4
|
4.62 (1.87, 11.42); I2 = 83.3%
|
|
CS infection comparator
|
2
|
2.07 (1.22, 3.53); I2 = 0.0%
|
|
No CR infection comparator
|
2
|
8.63 (4.12, 18.08); I2 = 31.6%
|
|
No infection comparator
|
1
|
6.92 (3.24, 14.79)
|
|
Longer-term (> 30 days) mortality
|
4
|
6.67 (3.88, 11.49); I2 = 0.0%
|
|
Italy
|
2
|
4.53 (0.78, 26.20); I2 = 93.3%
|
|
USA
|
3
|
5.19 (2.99, 9.01); I2 = 0.0%
|
|
Partially and totally high-risk patient populations
|
8
|
3.38 (1.93, 5.94); I2 = 76.0%
|
|
Low risk of bias
|
6
|
3.87 (2.10, 7.13); I2 = 76.9%
|
|
CS infection comparator
|
4
|
1.93 (1.24, 2.99); I2 = 8.2%
|
|
No CR infection comparator
|
2
|
8.63 (4.12, 18.08); I2 = 31.6%
|
|
No infection comparator
|
2
|
4.08 (1.56, 10.65); I2 = 76.5%
|
|
In-hospital/≤30-day mortality
|
4
|
2.05 (1.39, 3.02); I2 = 16.9%
|
|
Longer-term (> 30 days) mortality
|
4
|
6.67 (3.88, 11.49); I2 = 36.6%
|
|
CRKP studies only
|
7
|
3.45 (1.83, 6.51); I2 = 79.3%
|
|
Studies reporting HR
|
6
|
4.17 (2.23, 7.80); I2 = 76.6%
|
|
Studies reporting OR
|
2
|
1.71 (0.60, 4.82); I2 = 60.1%
|
|
Italy
|
2
|
4.53 (0.78, 26.20); I2 = 93.3%
|
|
USA
|
6
|
3.02 (1.79, 5.08); I2 = 54.2%
|
